Biotechnology Firm ImmuneWorks (Indiana) Begins National Clinical Trial for New Idiopathic Pulmonary Fibrosis (IPF) Treatment (10/19/2010)

Immuneworks was founded by Indiana University School of Medicine researchers to develop and commercialize treatments for serious autoimmune lung diseases.

ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial to evaluate the safety, tolerability, and biologic effects of three doses of IW001 in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotech company one step closer to commercialization of its lead IPF treatment compound. read more

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: